Cargando…

Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience

AIM: The aim of this study is to report our 10-year experience with transurethral needle ablation (TUNA) to evaluate its outcome on long-term basis. PATIENTS AND METHODS: A total of 351 patients’ records who underwent TUNA procedure for the management of benign prostatic hyperplasia were reviewed. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Haroun, Hossam, Eltatawy, Hassan, Soliman, M. G., Tawfik, Ahmed, Ragab, M. M., Ramadan, Ahmed, Sabaa, Magdy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476199/
https://www.ncbi.nlm.nih.gov/pubmed/31040608
http://dx.doi.org/10.4103/UA.UA_99_18
_version_ 1783412862509645824
author Haroun, Hossam
Eltatawy, Hassan
Soliman, M. G.
Tawfik, Ahmed
Ragab, M. M.
Ramadan, Ahmed
Sabaa, Magdy
author_facet Haroun, Hossam
Eltatawy, Hassan
Soliman, M. G.
Tawfik, Ahmed
Ragab, M. M.
Ramadan, Ahmed
Sabaa, Magdy
author_sort Haroun, Hossam
collection PubMed
description AIM: The aim of this study is to report our 10-year experience with transurethral needle ablation (TUNA) to evaluate its outcome on long-term basis. PATIENTS AND METHODS: A total of 351 patients’ records who underwent TUNA procedure for the management of benign prostatic hyperplasia were reviewed. The International Prostate Symptom Score (IPSS) and peak urinary flow rate were evaluated before the procedure, at 3 and 6 months postoperatively, and then yearly for 10 years. For patients complaining of de novo erectile dysfunction, the International Index of Erectile Function-5 was evaluated. Postoperative complications, number of patients who required additional therapeutic modality/other TUNA sessions, or those dropped out during follow-up were all recorded. RESULTS: Three hundred and fifty-one patients who underwent TUNA with fulfillment of our selection criteria were included in the study. The yearly records of included patients showed that patients’ baseline IPSS was significantly improved all over the follow-up years. Similarly, the maximum flow rate of the patients was significantly improved during the next 8 years. About 96.4% of patients who underwent TUNA did not require additional therapeutic modality/other TUNA sessions during the 1(st)-year follow-up. However, by 10 years, 26.4% of patients were offered another TUNA session and shifted to either medical therapy or other minimally invasive therapies. Mild hematuria was the most common complication (85.7%). Urinary retention, urethral stricture, and de novo erectile dysfunction were developed in 15.1%, 1.7%, and 6.8% of patients, respectively. There were no cases of retrograde ejaculation. CONCLUSION: TUNA can be considered as a relatively effective technique with a good safety profile. The current study demonstrated both significant subjective and objective improvements over 10 and 8 years of follow-up, respectively. It can be considered as a preferable option for patients who prefer surgical option with preservation of their sexual function and fertility.
format Online
Article
Text
id pubmed-6476199
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-64761992019-04-30 Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience Haroun, Hossam Eltatawy, Hassan Soliman, M. G. Tawfik, Ahmed Ragab, M. M. Ramadan, Ahmed Sabaa, Magdy Urol Ann Original Article AIM: The aim of this study is to report our 10-year experience with transurethral needle ablation (TUNA) to evaluate its outcome on long-term basis. PATIENTS AND METHODS: A total of 351 patients’ records who underwent TUNA procedure for the management of benign prostatic hyperplasia were reviewed. The International Prostate Symptom Score (IPSS) and peak urinary flow rate were evaluated before the procedure, at 3 and 6 months postoperatively, and then yearly for 10 years. For patients complaining of de novo erectile dysfunction, the International Index of Erectile Function-5 was evaluated. Postoperative complications, number of patients who required additional therapeutic modality/other TUNA sessions, or those dropped out during follow-up were all recorded. RESULTS: Three hundred and fifty-one patients who underwent TUNA with fulfillment of our selection criteria were included in the study. The yearly records of included patients showed that patients’ baseline IPSS was significantly improved all over the follow-up years. Similarly, the maximum flow rate of the patients was significantly improved during the next 8 years. About 96.4% of patients who underwent TUNA did not require additional therapeutic modality/other TUNA sessions during the 1(st)-year follow-up. However, by 10 years, 26.4% of patients were offered another TUNA session and shifted to either medical therapy or other minimally invasive therapies. Mild hematuria was the most common complication (85.7%). Urinary retention, urethral stricture, and de novo erectile dysfunction were developed in 15.1%, 1.7%, and 6.8% of patients, respectively. There were no cases of retrograde ejaculation. CONCLUSION: TUNA can be considered as a relatively effective technique with a good safety profile. The current study demonstrated both significant subjective and objective improvements over 10 and 8 years of follow-up, respectively. It can be considered as a preferable option for patients who prefer surgical option with preservation of their sexual function and fertility. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6476199/ /pubmed/31040608 http://dx.doi.org/10.4103/UA.UA_99_18 Text en Copyright: © 2019 Urology Annals http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Haroun, Hossam
Eltatawy, Hassan
Soliman, M. G.
Tawfik, Ahmed
Ragab, M. M.
Ramadan, Ahmed
Sabaa, Magdy
Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
title Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
title_full Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
title_fullStr Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
title_full_unstemmed Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
title_short Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
title_sort evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: a 10-year experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476199/
https://www.ncbi.nlm.nih.gov/pubmed/31040608
http://dx.doi.org/10.4103/UA.UA_99_18
work_keys_str_mv AT harounhossam evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience
AT eltatawyhassan evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience
AT solimanmg evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience
AT tawfikahmed evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience
AT ragabmm evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience
AT ramadanahmed evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience
AT sabaamagdy evaluationofoutcomeoftransurethralneedleablationfortreatingsymptomaticbenignprostatichyperplasiaa10yearexperience